SELL Natco Pharma Ltd — ICICI Securities
byICICI SecuritiesHorizon: NA (inferred 1 year)15 Nov 2025via Institutional / Brokerage Research
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this SELL call — facts from public sources, machine-classified. Not investment advice.
Natco Pharma Shares End 5% Lower As Q1 Results Spooks Investors; Dividend Declared
NewsNdtv-Profit·14 Aug · 3w ago
Natco Pharma Q1 profit falls 57 pc to Rs 206.5 cr
NewsEt-Markets·14 Aug · 3w ago
Natco Pharma shares fall over 6% after weak Q1 results; Board approves fund raise of up to ₹2,000 crore
NewsCnbc-Tv18·14 Aug · 3w ago
Natco Pharma Ltd's Board Meeting is scheduled for 09/09/2026 to consider and approve Fund Raising.
BSE · Board Meeting·4 Sept · 2d ago
Natco Pharma invests additional $14 million in eGenesis; total investment hits $22 million
NewsCnbc-Tv18·25 Aug · 2w ago
Here's why these four pharma stocks are in focus today
NewsCnbc-Tv18·24 Aug · 2w ago
Natco Pharma Ltd has successfully concluded a US FDA inspection at its Visakhapatnam Finished Dosage (FDF) Unit.
BSE · Company Update·21 Aug · 2w ago
Mazagon Dock, Marksans Pharma, NIIT Learning Systems, Natco Pharma Dividends: Last Day To Buy Shares To Qualify
NewsNdtv-Profit·19 Aug · 3w ago
Long-term trend bullish — 200-day average rising over the past quarter
Technicals · trend·4 Sept · 2d ago
Natco Pharma Limited is investing US$ 14 million in eGenesis, Inc. through its wholly owned subsidiaries, NATCO Pharma (Canada) Inc. and NATCO Pharma South Africa Proprietary Limited, via convertible
BSE · Company Update·25 Aug · 2w ago
Natco Pharma Limited is investing US$14 million in eGenesis, Inc. through its subsidiaries, increasing its total investment to US$22 million. eGenesis is a biotech company focused on genome engineerin
NSE · Press Release·25 Aug · 2w ago
1 other SEBI-registered advisor has an active long-term BUY call on this stock, issued in the last 14 days
Advisor consensus · same horizon·24 Aug · 2w ago
Natco Pharma gets 4 observations in US FDA inspection at Visakhapatnam facility
NewsCnbc-Tv18·21 Aug · 2w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.